Back to top

earnings-consensus: Archive

Zacks Equity Research

Ballard Power Systems (BLDP) Expected to Beat Earnings Estimates: Should You Buy?

Ballard (BLDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BLDPNegative Net Change EXCNegative Net Change

Zacks Equity Research

T. Rowe Price (TROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

T. Rowe (TROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TROWPositive Net Change VRTSPositive Net Change

Zacks Equity Research

Will Moderna (MRNA) Report Negative Earnings Next Week? What You Should Know

Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MRNAPositive Net Change BMYPositive Net Change

Zacks Equity Research

CBOE Global (CBOE) Reports Next Week: Wall Street Expects Earnings Growth

CBOE (CBOE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CBOEPositive Net Change ICEPositive Net Change

Zacks Equity Research

Exxon Mobil Holdings (XOM) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Exxon (XOM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

XOMNegative Net Change

Zacks Equity Research

Moog (MOG.A) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Moog (MOG.A) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MOG.APositive Net Change WWDPositive Net Change

Zacks Equity Research

Does Bioventus (BVS) Have the Potential to Rally 28.92% as Wall Street Analysts Expect?

The consensus price target hints at a 28.9% upside potential for Bioventus (BVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

BVSPositive Net Change

Zacks Equity Research

Wall Street Analysts See a 41.19% Upside in Abacus Global Management, Inc. (ABX): Can the Stock Really Move This High?

The mean of analysts' price targets for Abacus Global Management, Inc. (ABX) points to a 41.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

ABXPositive Net Change

Zacks Equity Research

Wall Street Analysts See a 36.87% Upside in Samsara Inc. (IOT): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 36.9% in Samsara Inc. (IOT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

IOTPositive Net Change

Zacks Equity Research

Wall Street Analysts See a 28.95% Upside in Grupo Financiero Galicia (GGAL): Can the Stock Really Move This High?

The consensus price target hints at a 29% upside potential for Grupo Financiero Galicia (GGAL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

GGALPositive Net Change